Beta-blockers have long been a mainstay of therapy for patients following myocardial infarction (MI). Their benefits in reducing mortality, limiting infarct size, and preventing arrhythmias were established in the pre-reperfusion era, particularly for patients with anterior MI or reduced left ventricular function. However, the management of post-MI patients has evolved. The widespread use of percutaneous coronary intervention (PCI), modern antiplatelet therapy, and high-intensity statins has improved outcomes, prompting a reassessment of whether all patients require long-term beta-blockers.
Author Sub-editor: Dr Pok-Tin Tang Dr Pok-Tin Tang is an ST5 cardiology registrar in the Thames Valley deanery, currently undertaking a period of out of
Author Sub-editor: Dr Jhiamluka Solano Dr Jhiamluka Solano is a cardiology resident doctor (ST6) in the Yorkshire and Humber Deanery, currently undertaking a DPhil (PhD)
Author Sub-editor: Dr Joshua Rowland Dr Joshua Rowland is a cardiology registrar working in the North West Deanery. He graduated from the University of Manchester
Author Sub-editor: Dr Atmadeep Banerjee Dr Atmadeep Banerjee is an ST4 Cardiology Registrar in the Kent, Surrey and Sussex deanery. He graduated from Calcutta National
